WHAT IS CLAIMED IS:

1. A compound of Formula IA:



Formula IA

or a pharmaceutically acceptable salt thereof, wherein

A is oxygen, sulfur or NR;

R is C_1-C_7alkyl, C_2-C_7alkenyl, C_2-C_7alkynyl, C_1-C_6haloalkyl, (C_3-C_{10}carbocycle)C_1-C_4alkyl or (4- to 7-membered heterocycloalkyl)C_1-C_4alkyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, oxo, C_1-C_4alkyl, C_1-C_4alkoxy and C_1-C_2alkoxycarbonyl;

x is 0, 1 or 2;

J, K and each occurrence of L are chosen from oxygen, sulfur, NH and CH_2; such that no more than one of J, K and L is chosen from oxygen, sulfur and NH;

R_1 is chosen from:

i) hydrogen, hydroxy, halogen, amino, cyano, nitro, -CHO, -$CONH_2$, C_1-C_6haloalkyl and C_1-C_6haloalkoxy;

ii) C_1-C_6alkyl, C_2-C_7alkenyl, C_2-C_7alkynyl, C_2-C_6alkanoyl, C_1-C_6alkoxy, (C_3-C_7cycloalkyl)C_0-C_4alkyl, (4- to 10-membered heterocycloalkyl)C_0-C_4alkyl, mono- and di-(C_1-C_6alkyl)aminoC_0-C_6alkyl, mono- and di-(C_1-C_6alkyl)carboxamide, C_1-C_6alkoxycarbonyl, -SO_n(C_1-C_6alkyl), -$NHSO_n$$C_1$-$C_6$alkyl, -($C_0$-$C_6$alkyl)$SO_n$($C_1$-$C_6$alkyl), -$SO_n$N($C_1$-$C_6$alkyl)($C_1$-$C_6$alkyl), and -$SO_n$-phenyl, wherein each n is independently 0, 1 or 2, and each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, oxo, C_1-C_4alkyl, C_1-C_4alkoxy and C_1-C_2alkoxycarbonyl; and

iii) naphthyl, phenyl and 5- to 10-membered heteroaryl, each of which is substituted with from 0 to 3 substituents independently chosen from R_{11};

R_2 and R_3 are independently hydrogen or C_1-C_6alkyl;

R_4 represents 1 substituent chosen from:

i) C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6alkoxycarbonyl, (C_3-C_7cycloalkyl)C_0-C_4alkyl and hexahydro-1,3-benzodioxolyl;

ii) aryl having 1 ring or 2 fused or pendant rings;

iii) (4- to 10-membered heterocycloalkyl)C_0-C_4alkyl;

iv) phenyl fused to a 5- to 7-membered saturated or partially unsaturated ring that (a) has 0, 1 or 2 ring atoms independently chosen from N, O and S, with remaining ring atoms being carbon, and (b) is substituted with from 0 to 3 substituents independently chosen from halogen, C_1-C_8alkyl, C_1-C_8alkoxy, C_1-C_8haloalkyl, C_1-C_8haloalkoxy;

v) (5- to 10-membered heteroaryl)C_0-C_4alkyl, having 1 ring or 2 fused or pendant rings, from 5 to 7 members in each ring, and in at least one ring from 1 to 3 heteroatoms independently selected from N, O, and S, wherein R_4 is not pyrimidyl; and

vi) groups that are taken together with an R_5 moiety to form a fused phenyl or pyridyl ring;

wherein each of i), ii), iii), iv), v) and vi) is substituted with from 0 to 3 substituents independently chosen from R_{11};

R_5 represents from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, nitro, -CHO, -$CONH_2$, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, C_1-C_6alkyl, C_1-C_6alkoxy, C_3-C_7cycloalkylC_0-C_4alkyl, mono- and di-(C_1-C_6alkyl)aminoC_0-C_6alkyl, optionally substituted phenyl, and groups that are taken together with R_4 to form a fused, optionally substituted phenyl or pyridyl ring; and

Ar_1 represents

i) phenyl or naphthyl, each of which is substituted with from 0 to 3 substituents independently chosen from amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, -COOH, -$CONH_2$, mono- and di-(C_1-C_4alkyl)amino, C_2-C_4alkanoyl, C_1-C_4sulfonate, C_1-C_4alkylsulfonyl, C_1-C_4alkylsulfinyl, C_1-C_4alkylthio, C_3-C_6alkanone, C_2-C_4alkyl ether, C_2-C_4alkanoyloxy, C_1-C_4alkoxycarbonyl and C_1-C_6alkylcarboxamide;

ii) phenyl fused to a 5- to 7-membered saturated or partially unsaturated ring that (a) has 0, 1 or 2 ring atoms independently chosen from N, O and S, with remaining ring atoms being carbon, and (b) is substituted with from 0 to 3 substituents independently chosen from halogen, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_2haloalkyl and C_1-C_2haloalkoxy; or

iii) heteroaryl, having 1 ring or 2 fused or pendant rings, from 5 to 7 members in each ring, and in at least one ring from 1 to 3 heteroatoms independently selected from N, O, and S;

wherein each of ii) and iii) is substituted with from 0 to 3 substituents independently chosen from R_{11}; and

R_{11} is independently chosen at each occurrence from hydroxy, halogen, amino, cyano, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, -COOH, -$CONH_2$, -SO_2NH_2, mono- and di-(C_1-C_6alkyl)amino, C_2-C_6alkanoyl, C_1-C_6sulfonate, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfinyl, C_1-C_6alkylthio, C_3-C_6alkanone, C_2-C_6alkyl ether, C_2-C_6alkanoyloxy, C_1-C_6alkoxycarbonyl and C_1-C_6alkylcarboxamide.

2. A compound or salt according to claim 1, wherein:

R is chosen from C_1-C_7alkyl, C_2-C_7alkenyl, C_2-C_7alkynyl, (C_3-C_7cycloalkyl)C_1-C_4alkyl and (4- to 7-membered heterocycloalkyl)C_1-C_4alkyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, oxo, C_1-C_4alkyl, C_1-C_4alkoxy and C_1-C_2alkoxycarbonyl;

R_1 is chosen from:

i) hydrogen, hydroxy, halogen, amino, cyano, nitro, -CHO, -$CONH_2$, C_1-C_6haloalkyl and C_1-C_6haloalkoxy;

ii) C_1-C_6alkyl, C_1-C_6alkenyl, C_1-C_6alkynyl, C_1-C_6alkoxy, (C_3-C_7cycloalkyl)C_0-C_2alkyl, (4- to 10-membered heterocycloalkyl)C_0-C_2alkyl, and mono- and di-(C_1-C_6alkyl)carboxamide, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, oxo, C_1-C_4alkyl and C_1-C_4alkoxy, and

iii) naphthyl, phenyl, pyridyl, thiazolyl, pyrimidinyl and thienyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, -COOH, -$CONH_2$, -SO_2NH_2, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_6alkanoyl, C_1-C_6alkylsulfonyl, C_1-C_6alkylsulfinyl, C_1-C_6alkylthio, C_3-C_6alkanone, C_2-C_6alkylether, C_2-C_6alkanoyloxy, C_1-C_6alkoxycarbonyl and C_1-C_6alkylcarboxamide;

R_4:

i) represents C_1-C_6alkyl, C_2-C_7alkenyl, C_2-C_7alkynyl, C_1-C_6alkoxycarbonyl, (C_3-C_7cycloalkyl)C_0-C_4alkyl, hexahydro-1,3-benzodioxolyl, phenyl, naphthyl or (4- to 7-membered heterocycloalkyl)C_0-C_4alkyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, -COOH, -$CONH_2$, mono- and di-(C_1-C_4alkyl)amino, C_2-C_4alkanoyl, C_1-C_4sulfonate, C_1-C_4alkylsulfonyl, C_1-

C_4alkylsulfinyl, C_1-C_4alkylthio, C_3-C_6alkanone, C_2-C_4alkyl ether, C_2-C_4alkanoyloxy, C_1-C_4alkoxycarbonyl, and C_1-C_6alkylcarboxamide; or

ii) is phenyl fused to a 5- to 7-membered saturated or partially unsaturated ring that (a) has 0, 1 or 2 ring atoms independently chosen from N, O and S, with remaining ring atoms being carbon, and (b) is substituted with from 0 to 3 substituents independently chosen from halogen, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_2haloalkyl and C_1-C_2haloalkoxy; or

iii) is taken together with an R_5 moiety to form a fused phenyl or pyridyl ring that is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, -COOH, -$CONH_2$, and mono- and di-(C_1-C_4alkyl)amino;

R_5 represents from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, -COOH, -$CONH_2$, mono- and di-(C_1-C_4alkyl)amino, and groups that are taken together with R_4 to form a fused, optionally substituted phenyl or pyridyl ring; and

Ar_1 represents phenyl, naphthyl, pyridyl, pyrimidinyl, pyridizinyl, pyrazinyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, pyrrolyl, oxazolyl, furanyl, indazolyl or thienyl, each of which is substituted with from 0 to 3 substituents independently chosen from amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, -COOH, -$CONH_2$, mono- and di-(C_1-C_4alkyl)amino, C_2-C_4alkanoyl, C_1-C_4sulfonate, C_1-C_4alkylsulfonyl, C_1-C_4alkylsulfinyl, C_1-C_4alkylthio, C_3-C_6alkanone, C_2-C_4alkyl ether, C_2-C_4alkanoyloxy, C_1-C_4alkoxycarbonyl and C_1-C_6alkylcarboxamide.

3. A compound or salt according to claim 1 or claim 2, wherein A is oxygen.

4. A compound or salt according to claim 1 or claim 2, wherein A is sulfur.

5. A compound or salt according to claim 1 or claim 2, wherein A is NR.

6. A compound or salt according to claim 1 or claim 2, wherein the compound satisfies Formula II:



Formula II.

7. A compound or salt according to claim 1 or claim 2, wherein the compound satisfies Formula III:



Formula III.

8. A compound or salt according to claim 1 or claim 2, wherein the compound satisfies Formula IV:



Formula IV.

9. A compound or salt according to claim 1 or claim 2, wherein the compound satisfies Formula V:



Formula V.

10. A compound or salt according to claim 1 or claim 2, wherein the compound satisfies Formula VI:



Formula VI.

11. A compound or salt according to claim 1 or claim 2, wherein the compound satisfies Formula VII:



Formula VII.

12. A compound or salt according to claim 1 or claim 2, wherein the compound satisfies Formula VIII:



Formula VIII

wherein:

K is CH_2 or NH; and

R_6 represents from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, C_1C_4alkyl, C_1-C_4alkoxy, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, -COOH, -$CONH_2$ and mono- and di-(C_1-C_4alkyl)amino.

13. A compound or salt according to claim 12, wherein A is NR and K is CH_2.

14. A compound or salt according to claim 1 or claim 2, wherein the compound satisfies Formula IX:



Formula IX.

15. A compound or salt according to claim 1 or claim 2, wherein the compound satisfies Formula X:



Formula X.

16. A compound or salt according to claim 1 or claim 2, wherein the compound satisfies Formula XI:



Formula XI.

17. A compound or salt according to claim 1 or claim 2, wherein the compound satisfies Formula XII:



Formula XII

wherein R_6 represents from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, C_1C_4alkyl, C_1-C_4alkoxy, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, -COOH, -$CONH_2$ and mono- and di-(C_1-C_4alkyl)amino.

18. A compound or salt according to any one of claims 1 to 17, wherein R_2 and R_3 are both hydrogen.

19. A compound or salt according to any one of claims 1 to 18, wherein Ar_1 is phenyl, pyridyl, indazolyl or thienyl, each of which is substituted with 0 to 3 substituents independently chosen from C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_2haloalkyl, C_1-C_2haloalkoxy and mono- and di-(C_1-C_2alkyl)amino.

20. A compound or salt according to claim 19, wherein Ar_1 is phenyl or mono- or di-substituted phenyl.

21. A compound or salt according to claim 20, wherein Ar_1 is phenyl substituted with one or two substituents independently chosen from ethyl and methyl.

22. A compound or salt according to claim 21, wherein Ar_1 is 2,6-disubstituted phenyl.

23. A compound or salt according to any one of claims 2 through 22, wherein R_1 is:

i) halogen;

ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_1-C_6alkoxy, (C_3-C_7cycloalkyl)C_0-C_4alkyl, pyrrolidinylC_0-C_2alkyl, morpholinylC_0-C_2alkyl, piperinylC_0-C_2alkyl or piperazinylC_0-C_2alkyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, oxo, C_1-C_4alkyl and C_1-C_4alkoxy; or

iii) phenyl or pyridyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, -COOH, -$CONH_2$, -SO_2NH_2, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, C_1-C_6alkyl, C_1-C_6alkoxy, and mono- and di-(C_1-C_4alkyl)amino.

24. A compound or salt according to claim 23, wherein R_1 is halogen, C_1-C_2alkyl, C_1-C_2alkoxy, or pyrrolidinylC_1-C_2alkyl.

25. A compound or salt according to claim 23, wherein R_1 is phenyl or pyridyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, -COOH, -$CONH_2$, -SO_2NH_2, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, C_1-C_6alkyl, C_1-C_6alkoxy, and mono- and di-C_1-C_4alkylamino.

26. A compound or salt according to any one of claims 5 through 25, wherein R is C_1-C_7alkyl, C_2-C_7alkenyl, (C_3-C_7cycloalkyl)C_1-C_4alkyl or (1,3-dioxylan-2-yl)C_1-C_4alkyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, oxo, C_1-C_4alkyl and C_1-C_4alkoxy.

27. A compound or salt according to claim 26 wherein R is C_1-C_5alkyl, C_2-C_4alkenyl or (1,3-dioxylan-2-yl)C_1-C_4alkyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, C_1-C_4alkyl and C_1-C_4alkoxy.

28. A compound or salt according to any one of claims 3 to 27, wherein R_4 is C_1-C_6alkyl, C_1-C_6alkoxycarbonyl or C_3-C_7 cycloalkyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, C_1-C_2alkyl, C_1-C_2alkoxy, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, -COOH, -$CONH_2$, and mono- and di-(C_1-C_4alkyl)amino.

29. A compound or salt according to any one of claims 3 to 27, wherein R_4 is phenylC_0-C_1alkyl, pyridylC_0-C_1alkyl, pyrimidylC_0-C_1alkyl, thienylC_0-C_1alkyl, naphthylC_0-C_1alkyl, indolylC_0-C_1alkyl, benzoxadiazolylC_0-C_1alkyl, benzoxazolylC_0-C_1alkyl, quinazolinylC_0-C_1alkyl, benzothiazolylC_0-C_1alkyl or benzimidazolylC_0-C_1alkyl, each of which is substituted with from 0 to 2 substituents independently chosen from hydroxy, halogen, amino, cyano, C_1-C_2 alkyl, C_1-C_2alkoxy, C_1-C_2haloalkyl, C_1-C_2haloalkoxy and mono- and di-(C_1-C_2alkyl)amino.

30. A compound or salt according to any one of claims 3 to 27, wherein R_4 is phenyl or pyridyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, -COOH, -$CONH_2$, mono- and di-(C_1-C_4alkyl)amino, C_2-C_4alkanoyl, C_1-C_4sulfonate, C_1-C_4alkylsulfonyl, C_1-C_4alkylsulfinyl, C_1-C_4alkylthio, C_3-C_6alkanone, C_2-C_4alkyl ether, C_2-C_4alkanoyloxy, C_1-C_4alkoxycarbonyl and C_1-C_6alkylcarboxamide.

31. A compound or salt according to claim 30, wherein R_4 is phenyl or pyridyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, C_1-C_4alkyl, C_1-C_2alkoxy, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, -COOH, -$CONH_2$, mono- and di-(C_1-C_2alkyl)amino, C_1-C_2alkoxycarbonyl and C_1-C_2alkylcarboxamide.

32. A compound or salt according to any one of claims 3 to 27, wherein R_4 is phenyl fused to a 5- to 7-membered saturated or partially unsaturated ring that (a) has 0, 1 or 2 ring atoms independently chosen from N, O and S, with remaining ring atoms being carbon, and (b) is substituted with from 0 to 3 substituents independently chosen from halogen, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy.

33. A compound or salt according to claim 32, wherein R_4 represents 1,3-benzodioxol-5-yl, 2,3-dihydro-1-benzofuran-6-yl, 2,3-dihydro-1-benzofuran-5-yl, 2,3-dihydro-1,4-benzodioxin-6-yl, chroman-6-yl, chroman-7-yl, 1,3-benzothiazolyl or 2,3-dihydroindol-5-yl, each of which is substituted with from 0 to 2 substituents independently selected from hydroxy, halogen, amino, cyano, oxo, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, C_1-C_2alkyl, C_1-C_2alkoxy and mono- and di-(C_1-C_2alkyl)amino.

34. A compound or salt according to claim 33, wherein R_4 is benzo[1,3]dioxol-5-yl or 2,3-dihydro-benzo[1,4]dioxin-6-yl, each of which is substituted with from 0 to 3

substituents independently chosen from halogen, C_1-C_2alkyl, C_1-C_2alkoxy, C_1-C_2haloalkyl and C_1-C_2haloalkoxy.

35. A compound or salt according to any one of claims 3 to 27, wherein R_4 is taken together with R_5 to form a fused phenyl or pyridyl ring that is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, -COOH, -$CONH_2$ and mono- and di-(C_1-C_4)alkylamino.

36. A compound or salt according to any one of claims 3 to 33, wherein R_5 represents from 0 to 3 substituents independently chosen from hydroxy, halogen, C_1-C_2alkyl, and C_1-C_2alkoxy.

37. A compound or salt according to any one of claims 1-35, wherein the compound exhibits an IC_{50} of 500 nM or less in a standard *in vitro* C5a receptor-mediated chemotaxis or calcium mobilization assay.

38. A compound or salt according to any one of claims 1-35, wherein the compound exhibits an IC_{50} of 25 nM or less in a standard *in vitro* C5a receptor-mediated chemotaxis or calcium mobilization assay.

39. A compound or salt according to any one of claims 1-35, wherein the compound exhibits less than 5% agonist activity in a GTP binding assay.

40. A pharmaceutical composition comprising at least one compound or salt according to any one of claims 1-35, in combination with a physiologically acceptable carrier or excipient.

41. A pharmaceutical composition according claim 40, wherein the pharmaceutical composition is formulated as an injectible fluid, an aerosol, a cream, a gel, a pill, a capsule, a syrup, or a transdermal patch.

42. A method for inhibiting signal-transducing activity of a cellular C5a receptor, comprising contacting a cell expressing C5a receptor with at least one compound or salt according to any one of claims 1-35, and thereby reducing signal transduction by the C5a receptor.

43. A method according to claim 42, wherein the cell is contacted *in vivo* in an animal.

44. A method according to claim 43, wherein the animal is a human.

45. A method for inhibiting binding of C5a to C5a receptor *in vitro*, the method comprising contacting C5a receptor with at least one compound or salt according to any one of claims 1-35, under conditions and in an amount sufficient to detectably inhibit C5a binding to C5a receptor.

46. A method for inhibiting binding of C5a to C5a receptor in a human patient, comprising contacting cells expressing C5a receptor with at least one compound or salt according to any one of claims 1-35, in an amount sufficient to detectably inhibit C5a binding to cells expressing a cloned C5a receptor *in vitro*, and thereby inhibiting binding of C5a to the C5a receptor in the patient.

47. A method for treating a patient suffering from rheumatoid arthritis, psoriasis, cardiovascular disease, reperfusion injury, or bronchial asthma comprising administering to the patient a C5a receptor modulatory amount of a compound or salt according to any one of claims 1-35.

48. A method for treating a patient suffering from stroke, myocardial infarction, atherosclerosis, ischemic heart disease, or ischemia-reperfusion injury comprising administering to the patient a C5a receptor modulatory amount of a compound or salt according to any one of claims 1-35.

49. A method for treating a patient suffering from cystic fibrosis or sepsis, comprising administering to a patient in need of such treatment a C5a receptor modulatory amount of a compound or salt according to any one of claims 1-35.

50. A method for inhibiting C5a receptor-mediated cellular chemotaxis, comprising contacting mammalian white blood cells with a C5a receptor modulatory amount of a compound or salt according to any one of claims 1-35.

51. A method for localizing C5a receptor in a tissue sample, comprising:

(a) contacting the tissue sample containing C5a receptor with a detectably labeled compound or salt according to any one of claims 1-35 under conditions that permit binding of the compound or salt to C5a receptors; and

(b) detecting the bound compound or salt.

52. A method according to claim 51, wherein the compound is radiolabeled.

53. A packaged pharmaceutical preparation, comprising:

(a) a pharmaceutical composition according to claim 40 in a container; and

(b) instructions for using the composition to treat a patient suffering from rheumatoid arthritis, psoriasis, cardiovascular disease, reperfusion injury, or bronchial asthma.

54. A packaged pharmaceutical preparation, comprising:

(a) a pharmaceutical composition according to claim 40 in a container; and

(b) instructions for using the composition to treat stroke, myocardial infarction, atherosclerosis, ischemic heart disease, or ischemia-reperfusion injury.

55. A packaged pharmaceutical preparation, comprising:

(a) a pharmaceutical composition according to claim 40 in a container; and

(b) instructions for using the composition to treat a patient suffering from cystic fibrosis or sepsis.